Royal Sense launches 10 new pharmaceutical products

Royal Sense Limited has announced the launch of 10 new pharmaceutical products, available for sale starting January 14, 2025. These products are targeted toward addressing various health concerns, reinforcing the company’s commitment to delivering high-quality and accessible healthcare solutions in the domestic market.

Product Launch Details:

Advertisement

  1. Ugmntin 625 Tablet: A combination of Amoxicillin and Clavulanic Acid for bacterial infections.
  2. Stergimox 250 Capsules: Contains Amoxicillin, effective against a range of bacterial infections.
  3. Trnxa Tablet: Uses Tranexamic Acid to prevent excessive bleeding by stabilizing blood clots.
  4. Trnxa MF Tablet: Combines Tranexamic Acid and Mefenamic Acid to address heavy menstrual bleeding and associated pain.
  5. NDEM 4 MG Tablets: Ondansetron-based treatment for nausea and vomiting caused by chemotherapy and surgery.
  6. EF.TUM 250 Tablets: Cefuroxime-based antibiotic for bacterial infections.
  7. JCZ-M Tablets: Combines Levocetirizine and Montelukast for allergies and asthma.
  8. ONLOX 200 Tablets: Ofloxacin-based antibiotic for bacterial infections.
  9. ONLOX OZ Tablets: A combination of Ofloxacin and Ornidazole for bacterial and parasitic infections.
  10. Mftal Tablets: Combines Mefenamic Acid and Dicyclomine to treat pain, inflammation, and muscle spasms.

Focus Areas:

  • Category: Pharmaceuticals
  • Market: Domestic

Official Statement:

Rishabh Arora, Managing Director of Royal Sense Limited, emphasized the company’s dedication to meeting the healthcare needs of the population through innovative solutions. These launches align with the company’s strategic goal of broadening its pharmaceutical portfolio.

The products aim to provide solutions for various medical needs, from bacterial infections to menstrual cramps and allergies, underscoring Royal Sense Limited’s mission to improve healthcare accessibility and outcomes.